Have been adding more to #N4P today. Plenty of news due in the next few months, which should help the market to realise the tremendous undervaluation here:
- Optimisation work on a more monodisperse formulation of DNA-loaded Nuvec
- Tech transfer to a manufacturing partner
1/3
- Optimisation work on a more monodisperse formulation of DNA-loaded Nuvec
- Tech transfer to a manufacturing partner
1/3
https://twitter.com/MylesMcNulty/status/1294217423969820673
- Possible update on collaboration with Nanomerics, re: 30-day stability testing;
- Update on potential routes to market for viral vector applications;
- Update on initial in-vitro work by Evotec on the potential oral application;
2/3
- Update on potential routes to market for viral vector applications;
- Update on initial in-vitro work by Evotec on the potential oral application;
2/3
- Possibility of a partnership with a #COVID19 vaccine developer even before the initial in-vivo data.
However, the valuation step change for #N4P will come following demonstration that Nuvec works well, and critically - consistently - in-vivo.
Suffice to say, I have faith! 3/3
However, the valuation step change for #N4P will come following demonstration that Nuvec works well, and critically - consistently - in-vivo.
Suffice to say, I have faith! 3/3
• • •
Missing some Tweet in this thread? You can try to
force a refresh
